Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06265545
NA

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

Sponsor: Institute of Hematology & Blood Diseases Hospital, China

View on ClinicalTrials.gov

Summary

To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

458

Start Date

2024-02-22

Completion Date

2028-06-30

Last Updated

2026-08-07

Healthy Volunteers

No

Interventions

DRUG

Ivosidenib

in arm 1

DRUG

Venetoclax

in arms 2-5

DRUG

Gilteritinib

in arm 2

DRUG

Homoharringtonine

in arms 4 and 7

DRUG

Cytarabine

in arms 3 and 7

DRUG

Daunorubicin/ Idarubicin /Mitoxantrone

in arms 3 and 7

DRUG

Azacitidine

in arms 1,2 , 5 and 8

DRUG

Lisaftoclax

in arms 7 and 8

DRUG

PI3K inhibitors, histone deacetylase inhibitors, selinexor, novel liposomal drugs, and others

in arm 6

Locations (1)

Blood Hospital

Tianjin, China